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ABSTRACT
Amyloids display a highly ordered fibrillar structure. Many of these assemblies appear associated 
with human disease. However, the controllable, stable, tunable, and robust nature of amyloid 
fibrils can be exploited to build up remarkable nanomaterials with a wide range of applications in 
biomedicine and biotechnology. Functional prions constitute a particular class of amyloids. These 
transmissible proteins exhibit a modular architecture, with a disordered prion domain responsible 
for the assembly and one or more globular domains that account for the activity. Importantly, the 
original globular protein can be replaced with any protein of interest, without compromising the 
fibrillation potential. These genetic fusions form fibrils in which the globular domain remains 
folded, rendering functional nanostructures. However, in some cases, steric hindrance restricts the 
activity of these fibrils. This limitation can be solved by dissecting prion domains into shorter 
sequences that keep their self-assembling properties while allowing better access to the active 
protein in the fibrillar state. In this review, we will discuss the properties of prion-like functional 
nanomaterials and the amazing applications of these biocompatible fibrillar arrangements.
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Amyloid proteins can self-assemble into ordered fibril-
lar structures. These amyloid fibrils, constitute 
a hallmark of human amyloidosis as well as of neuro-
degenerative diseases, including Alzheimer’s, 
Parkinson’s, Type Ⅱ diabetes, and others [1–3]. The 
discovery of functional amyloids in different organisms, 
from bacteria to humans, assisting different physiologi-
cal functions in living cells [4], has changed the amy-
loid/pathogenesis paradigm. For instance, functional 
amyloids are involved in curli-mediated biofilm forma-
tion in E. coli [5], memory persistence in Drosophila 
[6], hypersensitive response activation in plants [7], 
melanin polymerization in mammalian cells [8], and 
hormone storage in humans [9]. Amyloid fibrils display 
a remarkably similar quaternary structure, formed by 
the assembly of monomers into a characteristic ‘cross- 
β’ structure [10], resulting from the stacking of inter-
molecular β-sheets arrayed perpendicular to fibrils axis, 
which are stabilized by numerous hydrogen bonds 
between neighbouring strands [11], together with π-π 
and hydrophobic interactions [12]. Such a unique spa-
tial structure endows amyloid fibrils with high stability 
and high resistance to extreme physicochemical 
conditions, such as treatment with proteinases, chao-
tropic agents, and high temperatures[13]. These prop-
erties make amyloid fibrils ideal building blocks for 
designing novel protein/peptide self-assembled nanos-
tructures. Indeed, amyloid fibrils have been incorpo-
rated as structural components in functional materials 
with different biomedical and biotechnological applica-
tions, including nanodevices [14], biomembranes [15], 
hydrogels [16], biosensors [17], and energy conversion 
materials [18]. However, the inherent conformational 
transition towards a β-sheet rich structure during fibril-
lation necessarily implies the loss of the globular native 
fold and the subsequent inactivation of the protein. 
Therefore, designing fibrillar structures containing cor-
rectly folded and active proteins is still a challenging 
task. A way to bypass this limitation is by designing 
a hybrid structure in which the globular proteins are 
chemically attached to preformed amyloid fibrils [19]. 
However, this approach is restrained by a reduced pro-
tein conjugating chemistry, undesired cross-reactivity 
between the polypeptides, and the unavoidable inacti-
vation of a fraction of the protein during conjugation.
Prions are proteins able to switch between two or 
more conformations, of which at least one corresponds 
to an amyloid fold [20–22]. So far, only a prion protein 
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(PrP) has identified in mammals; PrP is well conserved 
across species and linked to different neurological 
pathologies [23]. Roughly ten prion proteins have 
been characterized in the yeast Saccharomyces cerevi-
siae. They are usually referred to as functional prions 
since, in contrast to ‘toxic’ mammalian prions, they do 
not seem to have a significant impact on viability, but 
instead, they play physiological roles, especially in the 
adaptation to changing extracellular environments 
[24,25]. They usually consist of an intrinsically unstruc-
tured region of low complexity enriched in asparagine 
(N) and glutamine (Q) residues, known as the prion 
domain (PrD), accompanied by one or more globular 
domains [26,27]. The PrD is both necessary and suffi-
cient for self-assembly, whereas the globular domain 
accounts for the protein functionality [28]. Yeast prions 
are thus modular and, in principle, the original globular 
domain can be replaced with any desired functional 
protein without impacting the fibrillation propensity 
significantly. Domains with properties resembling 
those of PrDs have been identified in the proteins of 
different organisms, including humans, and are named 
prion-like domains (PrLDs).
In contrast to the fast and challenging to control aggre-
gation reactions of pathogenic amyloids, prion and prion- 
like proteins generally display slow and tunable aggregation 
kinetics, which are considered optimal for the design of 
self-assembling materials [29]. Actually, different enzymes 
such as alkaline phosphatase (AP) [30], carbonic anhydrase 
(CA) [31], methyl-parathion hydrolase (MPH) [32] or 
other globular proteins like protein G and the Z domain 
[33] have been genetically fused to the PrDs of yeast prion 
Sup35 or Ure2p to generate functionalized nanomaterials 
in which the PrDs constitute the spine of the fibrils, 
whereas the globular domains hang from them in 
a folded and functional conformation. These materials 
are biocompatible, degradable, and environmentally 
friendly and can be employed in applications encompass-
ing from catalytic nanowires [30] to nanosensors [32]. 
Here, we summarize the features of functional prions in 
yeast and review the use of PrDs and PrLDs to generate 
genetically encoded functionalized nanomaterials and dis-
cuss their potential applications.
Functional prions in yeast
The concept of infectious proteins was initially pro-
posed to lie behind different neurological diseases, 
including Creutzfeldt-Jacob disease in humans, sheep 
scrapie and bovine spongiform encephalopathy, all 
caused by the amyloid state of the prion protein (PrP) 
[34–36]. Thus, prions were assumed to be pathogenic 
agents without any beneficial functional implication.
Initially, the phenotypes [PSI+] and [URE3] of yeast 
were identified as non-chromosomal genetic elements. 
Later on, Aigle and Lacroute reported that ure2 nuclear 
gene mutant strains were unable to propagate the 
[URE3] element but manifested the same phenotype 
as [URE3] cells, namely de-repression of nitrogen cat-
abolism genes[37]; however, they did not realize that 
[URE3] could be a prion of Ure2p. It was Reed 
B. Wickner, who, based on these pieces of evidence 
and his own experiments, recognized that the relation-
ship between ure2 and [URE3] was not that expected 
for a chromosomal gene necessary for the propagation 
of a nucleic acid replicon, but instead that [URE3] was 
an inactive form of Ure2p able to inactivate the normal 
protein form, acting thus as a prion [38,39]. Then his 
group inferred that this could also be true for the [PSI 
+] phenotype [38], and concluded that previous studies 
[40–42] supported [PSI+] being a prion of Sup35p. 
Moreover, they established a series of genetic criteria 
that identify yeast prions [43]: i) a reversible curability, 
ii) the phenotype appearance is induced by overexpres-
sion of the prion protein, and iii) the phenotype resem-
bles that of a prion protein gene recessive mutation.
These genetic criteria were useful for the discovery 
of a range of new prions including [PIN+] [44], [SWI+] 
[45], [MOT+] [46] and [MOD+] [24]. The formation of 
amyloid in vitro by Sup35p [47], and Ure2p [48], the 
protease resistance of Ure2p in [URE3] strains [49], 
together with the seeding properties of cellular extracts 
in [PSI+] [50], all converged to indicate that the prion 
form of these proteins was an amyloid. This assump-
tion was further confirmed after observing that in vitro 
formed Sup35p amyloids transmit the [PSI+] trait [51].
The inheritance of phenotypic traits due to prion 
formation involves a structural conversion, which in 
a majority of cases is driven by a Q/N rich PrD [52]. 
PrDs proved to be sufficient to induce and propagate 
the prion state. They become integrated into the core of 
the amyloid structure, which is thought to be arranged 
as an in-register parallel β-sheet architecture [10], 
according to nuclear magnetic resonance (NMR) and 
electron microscopy studies of the amyloids of Sup35p 
and Ure2p PrDs (Figure 1) [53,54]. The globular 
domains appended to the PrDs might retain their 
native structure in the amyloid filaments (Figure 1), 
although the activity of these domains was found to 
be somehow reduced, likely because of steric impedi-
ments [31]. Such folded, in-register parallel β-sheet 
architecture perfectly explains the mechanism of pro-
tein templating in prion conformational conversion 
(Figure 1) [55]. In particular, the favourable interac-
tions between hydrophobic or hydrophilic side chains 
along the long axis of the filament maintains the in- 
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register β-sheet structure. The same interactions force 
the new monomer to join the end of the filament to 
adopt the same conformation as the molecules already 
in the fibril, just as nucleic acids template their 
sequences [39]. An exception to this rule is the HET-s 
prion, from the filamentous fungi Podospora anserine, 
involved in heterokaryon incompatibility, protecting 
cells from fungal viruses [56]. The amyloid formed by 
the PrD of HET-s displays a β-helix structure, in which 
each monomer contributes two turns to the β-helix 
[57]. Recently, cryo-EM and computational studies sug-
gest that PrPSc would adopt a similar β-solenoid struc-
ture [58,59]. In fungal prions, the self-propagation of 
the prion phenotype during cell division is generally 
accomplished by the action of the chaperone system, 
which fragments existing fibrils, generating seeds that 
initiate the polymerization reaction in daughter cells 
[60,61].
The first and most studied of yeast prion proteins 
are Sup35p and Ure2p (Figure 1), involved in transla-
tion termination and nitrogen catabolism regulation, 
respectively [38]. Sup35p, a subunit of the translation 
termination factor, has a clear three-domain structure. 
The N-terminal residues 1–123 (Sup35 N) are sufficient 
to induce and propagate the [PSI+] prion phenotype 
and thus constitute the PrD. The C-terminal residues 
254–685 (Sup35 C), fold into a globular domain, 
Figure 1. Typical prions [URE3] and [PSI+] of S. cerevisiae. These prions rely on self-propagating amyloids of Ure2p and Sup35p, 
respectively. The insert is the proposed mechanism of conformational templating by the prion domain. Energetically favourable 
interactions between identical side chains enforce the in-register architecture of these amyloids. A new monomer being added to 
the end of the filament must assume the same conformation as that of molecules previously incorporated into the filament. 
(adapted with permission).[43]
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responsible for the translation termination function 
[62,63]. The charged middle domain (Sup35 M), corre-
sponding to residues 124 to 253, is important but not 
required for [PSI+] appearance and maintenance 
[64,65]. Sup35 N drives self-assembly of Sup35p into 
an amyloid, which results in a substantial reduction of 
its translation termination function and leads to an 
increase of nonsense codon readthrough. The PrD of 
Sup35p has itself a non-prion function, facilitating 
mRNA turnover. Ure2p has an architecture similar to 
that of Sup35p, including an N-terminal PrD (residues 
1–65) responsible for [URE3] formation [66] and 
a C-terminal domain (Ure2 C) structurally similar to 
glutathione transferase, but involved in repression of 
nitrogen catabolism genes by binding to the transcrip-
tion factor Gln3p, an interaction that is significantly 
impeded in the amyloid state [67].
The modular structure of yeast prions allows to 
dissect them in order to assess the prionogenic poten-
tial of other proteins and, in this way, identify new 
prions. This is performed by replacing the PrD or 
globular domain, via genetic engineering, with any 
desired polypeptide or reporter protein, such as the 
green fluorescent protein (GFP), to study the ability 
of the fusion protein to induce [PSI+]-like appearance 
or to visualize protein inclusions formation in cells 
[68]. These studies demonstrated that yeast prions 
could be easily engineered, immediately suggesting 
that they can be exploited in the design of self- 
assembling functionalized materials.
Prion-like nanomaterials obtained via genetic 
protein fusion
It has been reported that the yeast prion Ure2p exhibits 
glutathione peroxidase activity in both the native and 
fibrillar forms [69]. Besides, exogenous globular 
domains fused to the Ure2p PrD retain a native-like 
fold and show catalytic activity within in vitro formed 
amyloid filaments [31]. This ability to combine amyloid 
and globular folds in the aggregated state seems to be 
generic of yeast prions since the analysis of Sup35p 
amyloid filaments by cryo-EM, STEM [70], and solid 
state NMR [71], revealed that filaments of full length 
Sup35p indicated a thin fibril backbone surrounded by 
globular C-domains. The formation of a spatially 
defined fibrillar backbone and the segregation of folded 
globular domains are central for the design of prion- 
like self-assembling functionalized nanomaterials, with 
functions that include enzymatic catalysis [30], biosen-
sing [32], and protein binding [33]. The general strat-
egy to obtain the building blocks for such materials 
consists of the genetic fusion of a yeast prion PrD to 
a protein of interest and its recombinant production in 
microbial cell factories (Figure 2). The purified soluble 
fusion protein can self-assemble spontaneously into 
nanofibrils, which exhibit the function of the appended 
globular domain, under appropriate conditions of tem-
perature, pH, and agitation, in some instances, requir-
ing the presence of detergents.
Biosensors
The first prion-like nanomaterial obtained via genetic 
protein fusion was intended to work as a biosensor. 
Dong Men et al. [32] generated bifunctional protein 
nanowires (bFPNw) that displayed two different glob-
ular proteins: protein G and methyl-parathion hydro-
lase (MPH), which provide antibody binding and 
catalytic activities, respectively. They aimed to obtain 
fibrils with a high enzyme to protein G ratio. Towards 
this objective, both protein G and MPH were fused 
individually to the N-terminus of the Sup35p PrD 
(residues 1–61) and expressed as soluble monomers in 
E.coli. The fibrils formed by the self-assembly of the 
Sup351−61-protein G fusion were broken into small 
fragments to be used as seeds. The bFPNw exhibiting 
two different functions with different ratios were 
obtained by mixing these seeds and soluble Sup351−61- 
MPH in different proportions; this also allowed to tune 
the length of the fibrils. The biological activity of these 
bFPNw was tested by a typical ELISA assay, imple-
menting them instead of the classical enzyme- 
conjugated secondary antibody. As a general trend, 
Figure 2. The general genetic fusion approach for functiona-
lized nanomaterials. (a) Domain organization of the prion pro-
tein: soft amyloid core (SAC) (red) within the prion domain 
(PrD) (green) and the respective functional domains (purple) 
in a prion protein are shown. (b) Cartoon of the prion domain 
fused to molecule A, which represents a globular functional 
protein. (c) Soluble fusion protein self-assembly into nanofibrils, 
which preserve the function of molecule A.
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the longer the nanowires were, the higher the signal 
amplification they provided. In that work, optimized 
nanowires of 500 nm in length (ratio of protein G to 
MPH was 1:8) showed a sensitivity for the detection of 
the F1 protein from Yersinia pestis 1000-fold higher 
than that of a protein G-MPH fusion and 100-fold 
higher than that of the traditional HRP-conjugated 
antibody-based ELISA.
In subsequent work, the same group designed auto- 
biotinylated bFPNw by introducing a biotin avidin 
binding system, which can efficiently attach any avidin- 
labelled commercial enzyme, such as HRP or AP, to the 
nanowires backbone. This skips the need to produce 
and purify a different fusion for each intended applica-
tion[72]. In particular, the biotin acceptor peptide tag 
(BAP) and the IgG-binding domain, C1, of protein 
G from Streptococcus (SPG) were individually fused to 
the Sup35p PrD segment described above. The con-
struct Sup351−61-BAP was co-expressed in E.coli with 
another construct encoding for the biotin holoenzyme 
synthetase (BirA). In this way, the BAP tag was bioti-
nylated by BirA during the expression of the Sup351−61- 
BAP fusion. Instead of inducing the formation of 
bifunctional nanowires by seeding, which they found 
reduced the IgG binding activity of protein G because 
of the sonication processes, on this occasion, they just 
mixed the pre-formed biotinylated Sup351−61-BAP 
fibrils with the Sup351−61-SPG monomer, which was 
templated and incorporated at the end of the fibrils. 
The function of the bFPNw was evaluated by perform-
ing a typical ELISA in the presence of Streptavidin- 
HRP instead of the typical secondary IgG-HRP conju-
gate. For the detection of Y. pestis F1 antigen, the auto- 
biotinylated bFPNw showed higher signal intensity, 
lower background noise, and better signal stability 
than that of previous seeding promoted bFPNw. More 
importantly, they showed 2000- to 4000-fold higher 
sensitivity than that of a conventional ELISA.
The lessons learned in these two previous works 
were exploited to construct a highly sensitive fluores-
cent molecular biosensor. First, an F64 L/S65 T/ 
T203Y/L231 H green fluorescent protein mutant 
(E2GFP) was fused to MPH [73], E2GFP shows dis-
tinct excitation and emission spectra depending on 
the pH, which makes it an effective ratiometric pH 
indicator. The chimeric E2 GFP-MPH protein allowed 
the detection of the pesticide methyl parathion (MP) 
by sensing the H+ ions released during enzymatic 
reaction. Interestingly enough, when this chimeric 
protein was further fused to the Sup35p PrD and 
incorporated into fibrils through its self-assembly, 
the obtained nanowires showed dramatic enhance-
ment of sensitivity and allowed detection of MP at 
a concentration as low as 1pmol mL−1, which was 
about 10,000-fold that of the soluble fusion protein 
biosensor E2GFP-MPH and 107 -fold higher than the 
one of an equimolar mixture of free E2GFP and MPH 
moieties. These nanostructures might become tools 
for the detection of pesticides in the food industry.
Enzyme immobilization
Immobilization can enhance the value and usage of 
commercial enzymes, providing advantages such as an 
easy separation of the product and the reuse of the 
enzyme. The lab of Sarah Perrett has recently 
described PrD-based enzyme immobilization systems 
[30]. On this occasion, it was the PrD of Ure2p that 
was exploited to drive the self-assembly, and two 
different enzymes, AP and HRP, were individually 
fused to it. Both fusion proteins formed active nano-
fibrils, where the enzymes become immobilized. 
Although the fibrils exhibited slightly lower activity 
than that of the soluble wild type proteins, they could 
be recycled both in a conventional enzymatic setup 
and in the context of a continuous microreactor. In 
a follow up study, the authors encapsulated the solu-
ble PrD-AP protein fusion into a uniform droplet 
using microfluidic techniques [74]. The encapsulated 
soluble protein spontaneously self-assembled into 
a three-dimensional fibrillar network within the dro-
plet, immobilizing AP molecules in their active form. 
As a result, a catalytically active microgel with 
a porous architecture was obtained. These hydrated 
functional nanoparticles, when combined with micro-
fluidics, are ideal entities to implement microscale 
analytical assays.
Bioelectrodes
Vincent Forge and colleagues designed a protein-only 
redox biofilm inspired by the architecture of bacterial 
electroactive biofilms [75]. Briefly, the formation of the 
nanowires was induced by the self-assembly of the PrD 
of HET-s P. anserine prion, which was genetically fused 
to rubredoxin (Rd). This redox protein acts as an elec-
tron carrier. The formation of the fibrillar structures 
allowed the alignment of Rd along the fibril axis in an 
array, which facilitates the transportation of electrons 
through the network resulting in an exceptional con-
ductivity. As a proof of concept, such redox active 
fibrils were successfully applied to mediate the electron 
transfer towards the multi-cooper enzyme laccase for 
catalytic oxygen reduction. Therefore, these protein 
fibrils are expected to find applications as nanometric 
bioelectrodes.
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Antibody purification
The increasing demand of antibodies for diagnostic and 
therapeutic purposes requests cost efficient means for their 
purification. In recent work, Torleif Härd and co-workers 
exploited the small size and high affinity to IgG of the 
Z-domain from staphylococcal protein A to build up anti-
body capturing fibrils. A Z-domain dimer (ZZ) was fused 
to the PrD of either Sup35p (Sup35-ZZ) or Ure2p (ZZ- 
Ure2). Both of them promoted the fibrillation of the chi-
meric protein [33]. These fibrils bind to IgG, but their 
loading capacity was limited by steric hindrance. The 
PrDs of Sup35p and Ure2p were then co-fibrillated with 
chimeric Sup35-ZZ and ZZ-Ure2 proteins, respectively, to 
maximize the accessibility of antibodies to ZZ. This fibril 
doping strategy resulted in co-fibrils in which ZZ globular 
domains are more spaced in the fibrillar structure, thus 
maximizing the fibrils binding capacity (Figure 3). 
Different doping frequencies were assayed, and in the 
optimal PrD:protein fusion ratio, the resulting fibrils 
yielded a capture capacity of 1.8 mg of antibody per mg 
fibrils, which is 20-fold higher than the one of commercial 
protein A agarose.
Despite the exceptional binding capacity of ZZ functio-
nalized fibrils, this material should be produced and engi-
neered at large scale before it can commercially compete 
with the present well positioned methods for purification 
of antibodies. Towards this objective, the Härd lab inte-
grated both the Sup35-PrD and the chimeric Sup35-ZZ 
genes in the genome of Komagataella pastoris [76]. This 
yeast continuously expressed and secreted both proteins 
into the extracellular medium, where they co-fibrillated 
into ready-to-use functionalized nanofibrils, with an 
impressive production yield of 35 mg/L culture. 
Importantly, the separation of the fibrillar material from 
the cell culture required only centrifugation and their 
resuspension in a saline buffer. The high yield, high homo-
geneity, and high stability of the purified material, together 
with minimal equipment requirement and the low hands 
on time of this strategy, allows foreseeing, for the first time, 
the possibility of producing functional prion-like fibrils at 
an industrial scale.
Biocatalytic cascades
As discussed above, the chemistry-free covalent enzyme 
immobilization and the high surface to volume ratio of 
prion-based fibrils make of these nanostructures opti-
mal recyclable catalysers. However, many industrially 
relevant processes require two or more coupled reac-
tions, and, in most cases, only single-enzyme functio-
nalized fibrils have been characterized. Mats Sandgren 
and co-workers addressed this issue by building up 
a catalytic cascade by genetically fusing xylanase A, β- 
xylosidase, and aldose sugar dehydrogenase to the 
Sup35 PrD to create three different Sup35–enzyme 
chimeras [77]. As in the case of the Z-domain, the 
fibrils were doped with the PrD alone to introduce 
enough space between the functional enzyme molecules 
to eliminate steric restrictions. The objective was to 
convert beechwood xylan to xylonolactone, a valuable 
chemical for versatile applications, in three discrete 
enzymatic steps. Each type of functional fibril was 
formed individually, and then they were mixed in dif-
ferent proportions to maximize the catalytic efficiency. 
These investigations revealed that a sequential cascade 
in which fibrils of xylanase A and β-xylosidase were 
Figure 3. Schematic illustration of co-fibrillation to immobilize globular domains into amyloid fibrils with defined doping 
frequencies.
The chimeric protein consists of a prion-like domain (red) and a Z domain (green, antibody binding domain from Protein A, PDB 1Q2 N), 
linked via a flexible linker (blue). The chimeric protein is fibrillated with the carrier protein (the prion-like domain alone), in order to allow 
enough space between globular domains in the fibrils. This reduces steric constraints and maximizes the functionality. 
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first mixed, the resulting product of the coupled reac-
tion removed and then incubated with fibrils of aldose 
sugar dehydrogenase was more productive than 
a mixture containing all the three kinds of fibrils 
together since the immobilized enzymes displayed 
hardly compatible stabilities. Despite its limitations, 
this work constitutes of nice proof of concept for prion- 
inspired biocatalytic cascades.
Soft amyloid cores in PrDs and their use in 
nanomaterials
The absence of highly amyloidogenic sequences allows 
PrD to transit between soluble and aggregated states 
[78]. The aggregation of prions seems to depend on the 
establishment of a large number of weak interactions 
distributed along the complete PrD [79]. Accordingly, 
natural PrDs often consist of > 100 residues and 60 
residues was traditionally considered to be the mini-
mum length required to attain an efficient PrD self- 
assembly at moderate protein concentrations [46]. 
With this size, the PrD might constitute a significant 
fraction of the fusion protein, especially when it is fused 
to small globular domains, like the Z-domain. This 
results in steric restrictions in the fibrillar state since 
the amyloid spine may have a larger transversal dimen-
sion that the adjacent protein, a property that has been 
reported to reduce the diffusion of substrates and limit 
the functionality of the fibril[70]. Besides, large PrDs 
often compromise the solubility and stability of the 
appended globular domains in the monomeric fusions 
state, impacting the recombinant production of the 
chimeric proteins and their storage after purification.
We have recently proposed that inner weak amyloi-
dogenic sequence stretches within PrD might contri-
bute to nucleate the conformational conversion of 
prionic proteins into a cross-β structure [80]. These 
soft amyloid cores (SACs) (Figure 4), were first identi-
fied in yeast prions [81], but they are also present in 
a significant number of human prion-like proteins [82]. 
SACs differ from the classical short amyloid cores of 
pathogenic proteins, which hold a high aggregation 
propensity and are typically enriched in hydrophobic 
residues. SACs are slightly longer and more polar, 
resulting in a less concentrated aggregation potential. 
This allows the PrD to remain soluble under most 
physiological conditions, but also to hold a cryptic 
aggregation propensity that might facilitate its efficient 
self-assembly in response to cellular changes [78]. The 
SAC from Sup35p PrD consists of 21-residues and self- 
assembles spontaneously into highly ordered amyloid 
fibrils. These fibrils can seed the amyloid formation of 
the complete PrD in vitro. Also, when the in vitro 
formed SAC fibrils are added to yeast cells, they pro-
mote the aggregation of the endogenous full-length 
Sup35p and the subsequent emergence of a prionic 
phenotype [83]. Moreover, this region is necessary for 
the induction, propagation, and inheritance of the 
prion state of Sup35p in mammalian cytosol [84]. All 
these data converge to suggest that this short sequence 
stretch might have prion-like properties, which lead us 
to hypothesize that SACs can substitute the role of 
complete PrDs and recapitulate the self-assembly prop-
erties of the larger domain in the context of modular 
fusion proteins.
In recent work, we genetically fused the Sup35p SAC 
(Sup35SAC, Figure 4) to three globular proteins displaying 
different structures, namely the all-α FF domain (FF), the 
all-β green fluorescent protein (GFP) and the α/β carbonic 
anhydrase enzyme (CA) [85]. As expected, the low aggre-
gation propensity of the SAC allowed to express and purify 
the three fusions at high yields in a soluble and monomeric 
form, while still allowing to induce their self-assembly into 
amyloid fibrils under controlled conditions. As for com-
plete PrDs, the globular proteins adjacent to the SAC 
retained their native structures and functions in the fibrillar 
state. It is worth mentioning that Sup35SAC-CA fibrils 
displayed 3-fold higher catalytic activity than that of 
Sup35(1-61)-CA fibrils. This increased activity likely owes 
to the smaller size of SAC, which would result in less steric 
Figure 4. Soft amyloid core within the prion domain of Sup35p.
Sup35p consists of a prion domain (green box), a charged middle domain (black line) and a C-terminal globular domain with GTP-binding 
activity (blue oval). The identified soft amyloid core (SAC, red box) corresponds to the indicated 21-residues long sequence. 
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hindrance and increased accessibility of the appended 
enzyme to the substrate. This study illustrated how 
Sup35SAC could be used as a module to immobilize bioac-
tive proteins of different sizes and structures into highly 
functional amyloid fibrils. The high yield at which these 
fusions are produced and purified and the possibility to 
maintain them in a soluble state until the time we want to 
trigger the self-assembly reaction are significant advantages 
relative to full length PrD-based fusions.
Importantly, not only a vast diversity of natural 
SACs can be identified computationally [86], but these 
stretches can also be artificially engineered and mini-
mized, provided that we keep their main physicochem-
ical traits. For instance, we have designed a family of 
minimalist SAC-inspired polar heptapeptides that self- 
assemble into amyloid fibrils. The nice thing of these 
nanowires is that, if they are adequately designed, they 
can be endorsed with intrinsic catalytic activity, without 
the need for an adjacent globular domain [87].
Conclusions
In the present review, we have discussed how the 
genetic protein fusion strategy has resulted in the devel-
opment of PrD-based functionalized nanomaterials 
with exceptional properties as enzyme immobilizers, 
biosensors, bioelectrodes or for antibody purification 
and antigens detection. We are convinced that the 
application of these unique materials in fields like 
nanomedicine or nanotechnology will expand signifi-
cantly in the forthcoming years, especially because the 
use of natural and artificial SACs might allow us to 
potentially endorse nanofibrils with a new set of pre-
viously inaccessible functionalities.
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